FADS1: Unlocking The Potential Therapeutic Potential of Peroxisome- Producing Enzyme

Target Name: FADS1

NCBI ID: G3992

FADS1

FADS1: Unlocking The Potential Therapeutic Potential of Peroxisome- Producing Enzyme

FADS1 (Delta-5 desaturase) is a gene that encodes a protein in the peroxisome, a organelle responsible for the production of fatty acids and other molecules. Mutations in the FADS1 gene have been linked to a variety of diseases, including obesity, type 2 diabetes, and certain inherited conditions. As a result, FADS1 has become a focus of research in the field of pharmacology, with efforts to develop drugs that target FADS1 as a potential therapeutic approach.

The peroxisome is an organelle that is responsible for the production of a variety of molecules, including fatty acids, which are essential for a wide range of cellular functions. The peroxisome is composed of a number of different subunits, including the N-acyltransferase A ( NAT) complex, which is responsible for converting unsaturated fatty acids into saturated fatty acids. One of the key components of the NAT complex is FADS1, which is a protein that plays a central role in the production of fatty acids from unsaturated sources.

FADS1 is a member of the Superfamily A (SA) of the nitric oxide biosynthetic enzyme (NBS) gene family. This family of proteins includes a number of different enzymes that are involved in the production of a variety of different molecules, including fatty acids, from unsaturated sources. FADS1 is characterized by a single polypeptide chain that contains a number of different domains, including an N-terminus, a catalytic center, and a C-terminus.

The N-terminus of FADS1 is a region that is involved in the coordination of the protein with various co-factors and co-factors that are involved in the production of fatty acids. The catalytic center of FADS1 is the site where the protein carries out the chemical reaction that is responsible for the production of fatty acids from unsaturated sources. This reaction involves the transfer of a carbon atom from the unsaturated fatty acid to a cofactor, such as NAD+ or FAD, which is then reduced to a fatty acid.

FADS1 has been shown to play a central role in the production of fatty acids from unsaturated sources in the peroxisome. In addition to its role in the production of fatty acids, FADS1 is also involved in the regulation of a number of different cellular processes, including the production of reactive oxygen species (ROS) and the detoxification of xenobiotics.

Mutations in the FADS1 gene have been linked to a variety of different diseases, including obesity, type 2 diabetes, and certain inherited conditions. For example, studies have shown that individuals with certain genetic mutations, such as those in the FADS1 gene, are more likely to be overweight or obese and to have type 2 diabetes. In addition, research has also shown that individuals with certain inherited conditions, such as the superoxide dismutase (SOD) gene mutation, are more likely to have mutations in FADS1 and to be at increased risk for the development of certain diseases.

Given the importance of FADS1 in the production of fatty acids and its role in a variety of different cellular processes, efforts have been underway to develop drugs that target FADS1 as a potential therapeutic approach. One approach to developing such drugs is to use small molecules, such as inhibitors of the FADS1 enzyme, to disrupt the production of fatty acids from unsaturated sources. This approach has been shown to be effective in animal models of a variety of different diseases, including obesity and type 2 diabetes.

Another approach to developing drugs that target FADS1 is to use genetic modifiers, such as CRISPR/Cas9 technology, to modify the FAD

Protein Name: Fatty Acid Desaturase 1

Functions: Acts as a front-end fatty acyl-coenzyme A (CoA) desaturase that introduces a cis double bond at carbon 5 located between a preexisting double bond and the carboxyl end of the fatty acyl chain. Involved in biosynthesis of highly unsaturated fatty acids (HUFA) from the essential polyunsaturated fatty acids (PUFA) linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3) precursors. Specifically, desaturates dihomo-gamma-linoleoate (DGLA) (20:3n-6) and eicosatetraenoate (ETA) (20:4n-3) to generate arachidonate (AA) (20:4n-6) and eicosapentaenoate (EPA) (20:5n-3), respectively (PubMed:10601301, PubMed:10769175). As a rate limiting enzyme for DGLA (20:3n-6) and AA (20:4n-6)-derived eicosanoid biosynthesis, controls the metabolism of inflammatory lipids like prostaglandin E2, critical for efficient acute inflammatory response and maintenance of epithelium homeostasis. Contributes to membrane phospholipid biosynthesis by providing AA (20:4n-6) as a major acyl chain esterified into phospholipids. In particular, regulates phosphatidylinositol-4,5-bisphosphate levels, modulating inflammatory cytokine production in T-cells (By similarity). Also desaturates (11E)-octadecenoate (trans-vaccenoate)(18:1n-9), a metabolite in the biohydrogenation pathway of LA (18:2n-6) (By similarity)

The "FADS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FADS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets